GAITHERSBURG, Maryland (Reuters) - The widespread use of anemia drugs sold by Amgen Inc (AMGN.O: Quote, Profile, Research) and Johnson & Johnson (JNJ.N: Quote, Profile, Research) should be sharply restricted for cancer patients amid serious safety concerns, a U.S. advisory panel said on Thursday.
